Companies/Syndax Pharmaceuticals, Inc.

Company profile

Syndax Pharmaceuticals, Inc.

NASDAQ: SNDX · Healthcare · Biotechnology

PublicHQ New York City, MACIK 0001395937Reports USD

#297 of 1,394 Healthcare companies by revenuetop-decile growth

EA Score

52D

FH 36DQ 73GM 49SS 70

v0.1 · 65/100 weight · provisional

↑ revenue growth (YoY), filing timeliness · ↓ growth stability, return on equity

Methodology →

Revenue TTM

$217.2M

Rev growth YoY (TTM)

+396.7%

Net income (FY)

-$285.4M

Employees

270

Market cap

$1.9B

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$172.4M$172.4M2025

Net income-$285.4M-$285.4M2025

Operating income-$273.1M-$273.1M2025

Total assets$529.7M$529.7M2025

Liabilities$465.1M$465.1M2025

Equity$64.6M$64.6M2025

Revenue trend

FY2020 – FY2025 · USD

$379.0k

FY20

$379.0k

FY20

$1.5M

FY20

$139.7M

FY21

FY23

$23.7M

FY24

$172.4M

FY25

Revenue by segment

Filed disclosures · FY2025

By product

Net Product Revenues72%

Collaboration revenue25%

Milestone Revenue3%

By geography

Not disclosed.

The read

Syndax Pharmaceuticals, Inc. booked $172.4M in FY2025 revenue, growing 628% year over year — faster than 95% of Healthcare companies we track, at a -165.6% net margin.

Peers · Healthcare

Zymeworks Inc.54D Rest Ez Inc.——MBX Biosciences, Inc. Common Stock——ANI Pharmaceuticals, Inc.82B+

Key facts

CEOMichael A. Metzger

SectorHealthcare

IndustryBiotechnology

HeadquartersNew York City, MA

ExchangeNASDAQ: SNDX

Employees270

IPO date2016-03-02

Latest filings

8-K2026-06-10 8-K2026-06-10 8-K2026-06-04 DEF 14A2026-04-30 10-Q2026-04-30 8-K2026-04-30 8-K2026-02-26 10-K2026-02-26

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.